Good results prompt Millennium to end Velcade trial

09/18/2007 | Forbes

Millennium Pharmaceuticals has decided to stop the Phase III trial of its cancer drug Velcade on positive results from combining the injectable treatment with other drugs. The company noted promising interim results in testing Velcade in combination with the chemotherapy drug melphalan and the corticosteroid prednisone among newly diagnosed multiple myeloma patients.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA